» Articles » PMID: 28441013

Cytotoxicity of Pyrazine-Based Cyclometalated (C^N^C)Au(III) Carbene Complexes: Impact of the Nature of the Ancillary Ligand on the Biological Properties

Overview
Journal Inorg Chem
Specialty Chemistry
Date 2017 Apr 26
PMID 28441013
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The synthesis of a series of cyclometalated gold(III) complexes supported by pyrazine-based (C^N^C)-type pincer ligands is reported, including the crystal structure of a cationic example. The compounds provide a new platform for the study of antiproliferative properties of gold(III) complexes. Seven complexes were tested: the neutral series (C^N^C)AuX [X = Cl (1), 6-thioguanine (4), C≡CPh (5), SPh (6)] and an ionic series that included the N-methyl complex [(C^N^C)AuCl]BF (7) and the N-heterocyclic carbene complexes [(C^N^C)AuL] with L = 1,3-dimethylbenzimidazol-2-ylidene (2) or 1,3,7,9-tetramethylxanthin-8-ylidene (3). Tests against human leukemia cells identified 1, 2, 3, and 4 as particularly promising, whereas protecting the noncoordinated N atom on the pyrazine ring by methylation (as in 7) reduced the cytotoxicity. Complex 2 proved to be the most effective of the entire series against the HL60 leukemia, MCF-7 breast cancer, and A549 lung cancer cell lines, with IC values down to submicromolar levels, associated with a lower toxicity toward healthy human lung fibroblast cells. The benzimidazolylidene complex 2 accumulated more effectively in human lung cancer cells than its caffeine-based analogue 3 and the gold(III) chloride 1. Compound 2 proved to be unaffected by glutathione under physiological conditions for periods of up to 6 days and stabilizes the DNA G-quadruplex and i-motif structures; the latter is the first such report for gold compounds. We also show the first evidence of inhibition of MDM2-p53 protein-protein interactions by a gold-based compound and identified the binding mode of the compound with MDM2 using saturation transfer difference NMR spectroscopy combined with docking calculations.

Citing Articles

Small molecule targeted therapies for endometrial cancer: progress, challenges, and opportunities.

Yang F, Zhao T, Milaneh S, Zhang C, Xiang D, Wang W RSC Med Chem. 2024; 15(6):1828-1848.

PMID: 38911148 PMC: 11187550. DOI: 10.1039/d4md00089g.


Organometallic gold(I) and gold(III) complexes for lung cancer treatment.

Zhang J, Li Y, Fang R, Wei W, Wang Y, Jin J Front Pharmacol. 2022; 13:979951.

PMID: 36176441 PMC: 9513137. DOI: 10.3389/fphar.2022.979951.


Current Developments of -Heterocyclic Carbene Au(I)/Au(III) Complexes toward Cancer Treatment.

Tialiou A, Chin J, Keppler B, Reithofer M Biomedicines. 2022; 10(6).

PMID: 35740438 PMC: 9219884. DOI: 10.3390/biomedicines10061417.


Breast Cancer Treatment: The Case of Gold(I)-Based Compounds as a Promising Class of Bioactive Molecules.

Galassi R, Luciani L, Wang J, Vincenzetti S, Cui L, Amici A Biomolecules. 2022; 12(1).

PMID: 35053228 PMC: 8774004. DOI: 10.3390/biom12010080.


Osmium Arene Germyl, Stannyl, Germanate, and Stannate Complexes as Anticancer Agents.

Nabiyeva T, Roufosse B, Odachowski M, Baumgartner J, Marschner C, Verma A ACS Omega. 2021; 6(29):19252-19268.

PMID: 34337263 PMC: 8320079. DOI: 10.1021/acsomega.1c02665.


References
1.
Messori L, Orioli P, Tempi C, Marcon G . Interactions of selected gold(III) complexes with calf thymus DNA. Biochem Biophys Res Commun. 2001; 281(2):352-60. DOI: 10.1006/bbrc.2001.4358. View

2.
Phan A, Mergny J . Human telomeric DNA: G-quadruplex, i-motif and Watson-Crick double helix. Nucleic Acids Res. 2002; 30(21):4618-25. PMC: 135813. DOI: 10.1093/nar/gkf597. View

3.
Tao J, Perdew J, Staroverov V, Scuseria G . Climbing the density functional ladder: nonempirical meta-generalized gradient approximation designed for molecules and solids. Phys Rev Lett. 2003; 91(14):146401. DOI: 10.1103/PhysRevLett.91.146401. View

4.
Liu D, Balasubramanian S . A proton-fuelled DNA nanomachine. Angew Chem Int Ed Engl. 2003; 42(46):5734-6. DOI: 10.1002/anie.200352402. View

5.
Sun H, Zhang L, Szeto K . Bismuth in medicine. Met Ions Biol Syst. 2004; 41:333-78. View